Antibodies News and Research

RSS

Research finding could lead to development of vaccine and therapies for mucormycosis

Mucormycosis is a deadly infection that strikes people with weakened immune systems when certain types of fungi, called Mucorales, invade the patients' cells. A novel protein on the surface of the Mucorales cells, called CotH, makes this invasion possible.

22 Dec 2013

Studies yield new insights into molecular mechanisms that underlie learning process

Learning requires constant reconfiguration of the connections between nerve cells. Two new studies now yield new insights into the molecular mechanisms that underlie the learning process.

22 Dec 2013

Researchers make new breakthrough in HIV vaccine research

A vaccine study in monkeys designed to identify measurable signs that the animals were protected from infection by SIV, the monkey version of HIV, as well as the mechanism of such protection has yielded numerous insights that may advance HIV vaccine research.

20 Dec 2013

Scientists explore ways to tackle bacterium that causes diarrhea, vomiting, stomach pain

Scientists want to make a chink in the armor of a bacterium that has little name recognition yet is the number-one bacterial cause of the diarrhea, vomiting and stomach pain Americans experience annually.

20 Dec 2013

Researchers develop oral vaccine against Helicobacter pylori

Researchers from Southern Medical University in Guangdong, Guangzhou, China, have developed an oral vaccine against Helicobacter pylori, the bacteria responsible for peptic ulcers and some forms of gastric cancer, and have successfully tested it in mice. The research is published ahead of print in the journal Clinical and Vaccine Immunology.

20 Dec 2013

BeiGene doses first patient in Phase 1 study of BGB-283

BeiGene (Beijing), Co., Ltd., today announced dose administration for the first patient in a Phase 1 study of BGB-283 in patients with B-RAF or K-RAS mutations. BGB-283 is an investigational, oral, selective, potent second generation inhibitor of B-RAF, making it a targeted therapeutic candidate to potentially treat and bring benefit to patients with cancers that harbor BRAF mutations and/or aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway.

20 Dec 2013

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Baxter International Inc. today announced that the United States Food and Drug Administration granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.

From Baxter International Inc. 20 Dec 2013

Sorrento Therapeutics acquires Concortis Biosystems

Sorrento Therapeutics, Inc. announced today that it has completed its acquisition of Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates with site-specific toxin conjugation and consistent drug-antibody ratios. With the close of the deal, Sorrento has issued an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Based on the closing share price on December 18, 2013, the transaction is valued at $11.3 million.

19 Dec 2013

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Omeros Corporation today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration for prevention of complement-mediated thrombotic microangiopathies.

18 Dec 2013

Researchers produce first definitive evidence that MERS-CoV infects camels

Scientists from the Netherlands and Qatar have produced the first definitive evidence that Middle East respiratory syndrome coronavirus infects camels. The researchers used gene-sequencing techniques to show that three camels from a site where two humans contracted MERS-CoV were infected with the virus.

18 Dec 2013

Researchers discover control mechanism that can trigger development of MDS

Researchers at the Moffitt Cancer Center have discovered a control mechanism that can trigger the development of myelodysplastic syndromes (MDS), a group of blood cancers. This finding may lead to therapies capable of preventing the progression of these diseases.

17 Dec 2013

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin gene in development for the treatment of TTR-mediated amyloidosis.

17 Dec 2013

Scientists find vaccine that blocks invasion of blood cell by Malaria parasite

Scientists from Singapore's Nanyang Technological University (NTU) have discovered a key process during the invasion of the blood cell by the Malaria parasite, and more importantly, found a way to block this invasion.

16 Dec 2013

NTU researchers find way to block invasion of Malaria parasite in blood cells

Scientists from Singapore's Nanyang Technological University have discovered a key process during the invasion of the blood cell by the Malaria parasite, and more importantly, found a way to block this invasion.

16 Dec 2013

Vaccines for whooping cough contain 3 to 5 protective antigens

Vaccines for whooping cough contain three to five protective antigens, the presence of which are critical to the vaccine's effectiveness. But one of the antigens, pertactin, which had been present in almost all isolates of Bordetella pertussis in the US as late as 2010, is now absent from more than half of them, according to a paper published ahead of print in Clinical and Vaccine Immunology.

13 Dec 2013

Marker for inflammatory bowel disease linked to bipolar disorder

Researchers have found evidence that the gastrointestinal tract plays a role in the inflammatory pathology of bipolar disorder, suggesting the need to consider dietary modification and anti-inflammatory treatment for some patients.

12 Dec 2013

Researchers discover new therapeutic approach for hemophilia

Researchers at the UNC School of Medicine and the Medical College of Wisconsin found that a new kind of gene therapy led to a dramatic decline in bleeding events in dogs with naturally occurring hemophilia A, a serious and costly bleeding condition that affects about 50,000 people in the United States and millions more around the world.

12 Dec 2013

Wolfberries appear to interact with vaccine to offer protection against flu virus in older mice

In a study of older mice, wolfberries appear to interact with the influenza vaccine to offer additional protection against the flu virus. The research, led by scientists at the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HNRCA) at Tufts University, suggests the wolfberry may increase the activity of dendritic cells, which play an important role in the ability of the immune system to defend against viral infections.

12 Dec 2013

Synthetic Biologics prices underwritten public offering of common stock at $1.00 per share

Synthetic Biologics, Inc., a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today the pricing of an underwritten public offering of 11,500,000 shares of common stock at a public offering price of $1.00 per share.

12 Dec 2013

Crealta to acquire all assets of Savient Pharmaceuticals

Savient Pharmaceuticals, Inc. ("Savient") announced that it has reached agreement on the terms of an acquisition agreement with Crealta Pharmaceuticals LLC ("Crealta") through which Crealta would acquire substantially all of the assets of Savient, including all KRYSTEXXA® assets, for gross proceeds of approximately $120.4 million.

11 Dec 2013